Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Calithera Biosciences, Inc. (CALA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/14/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights"
08/05/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights — Cash and Cash Equivalents Totaled $92.2 million as of June 30, 2021 — — Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021— SOUTH SAN FRANCISCO, Calif., August 5, 2021 - Calithera Biosciences, Inc. , a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the second quarter ended June 30, 2021. “In the second quarter, we announced a license agreement with Antengene for the development of CB-708, a potential first-in-class oral small molecule CD73 inhibitor developed internally via our drug discovery engine,”..."
05/06/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on November 5, 2020— SOUTH SAN FRANCISCO, Calif., November 5, 2020 - Calithera Biosciences, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the third quarter ended September 30, 2020. “To date, 2020 has been a significant year for Calithera as we've made remarkable progress to advance our clinical development efforts across our pipeline and work toward reporting our first pivotal trial results with our lead candidate glutaminase inhibitor telaglenas..."
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 9, 2019 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#9...",
"Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019— SOUTH SAN FRANCISCO, Calif., May 9, 2019 - Calithera Biosciences, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways, announced today its financial results for the first quarter ended March 31, 2019. As of March 31, 2019, cash equivalents and investments totaled $117.0 million. “This year we expect to achieve multiple, key milestones in our clinical development program and several data readouts, including top-line results of the ENTRATA trial mid-year, and with our partner Incyte, data from the INCB0..."
03/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 7, 2019 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &...",
"Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights"
11/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2018 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ...",
"Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights"
08/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 7, 2018 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ...",
"Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights"
05/10/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights"
03/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights"
11/02/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 2, 2017 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ...",
"Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights"
08/08/2017 8-K Quarterly results
Docs: "Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights"
05/09/2017 8-K Form 8-K - Current report
03/16/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/09/2016 8-K Form 8-K - Current report
05/10/2016 8-K Form 8-K - Current report
03/15/2016 8-K Form 8-K - Current report
11/09/2015 8-K Form 8-K - Current report
08/10/2015 8-K Form 8-K - Current report
05/07/2015 8-K Form 8-K - Current report
03/26/2015 8-K Form 8-K - Current report
11/14/2014 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy